ライフサイエンスコーパス: NDV

1 NDV grown in RCA-expressing cells was resistant to compl

2 NDV HN has two sialic acid binding sites: site I, which

3 NDV infection (which induces alpha interferon) had the s

4 NDV is particularly attractive because while it is patho

5 NDV's selective replication in tumor cells has been prev

6 NDV-3 induced increases in CD3+ T-cell and neutrophil in

7 NDV-3A, a novel fungal vaccine undergoing clinical trial

8 NDV-infected cells also upregulated several genes not pr

9 solates from this outbreak (NDV-Belize-3/08, NDV-Belize-4/08, and NDV-Belize-12/08) were assessed by

10 Avian paramyxovirus type 1, NDV, has been an attractive oncolytic agent for cancer v

11 en/DominicanRepublic(JuanLopez)/499-31/2008 (NDV-DR499-31/08), and the fusion proteins of three other

12 In this study, 27 NDV isolates collected from apparently healthy chickens

13 In addition, NDV infection tended to lower the variance in AI among D

14 Here we developed additional NDV-vectored vaccines expressing either HPAIV HA in whic

15 and is a promising vaccine candidate against NDV strains circulating in Indonesia.

16 3 alone can provide cross-protection against NDV challenge.

17 lent vaccine vector that can be used against NDV and other poultry pathogens.

18 Although all NDV isolates characterized to date belong to a single se

19 Compared with adjuvant alone, NDV-3 reduced abscess progression, severity, and MRSA de

20 Although NDV vaccines exist, there are frequent reports of outbre

21 Although NDV-Peru/08 is a genetically distinct virus, pathogenesi

22 ymerase (L) genes in a complete genome of an NDV isolate from this geographical region.

23 tial environmental and economic impact of an NDV outbreak have precluded its clinical development.

24 We showed that a regimen consisting of an NDV prime followed by a protein boost elicited stronger

25 break (NDV-Belize-3/08, NDV-Belize-4/08, and NDV-Belize-12/08) were assessed by genomic analysis and

26 ficant enhancement of oncolytic activity and NDV replication.

27 with rLS/AMPV-C F&G induced both AMPV-C and NDV-specific antibody responses, and provided significan

28 as having NiV G-derived globular domains and NDV HN-derived stalks, transmembranes, and cytoplasmic t

29 disease virus (NDV)-vectored H7 (NDV-H7) and NDV-H5 vaccines are able to induce antibodies with high

30 e show that MORC3 is induced by both IFN and NDV infection in PVK cells but is not induced by either

31 nferred complete protection against ILTV and NDV challenge.

32 ree vaccine viruses [NDV/HA, NDV/HA(RV), and NDV/NA] were administered separately to groups of Africa

33 ntaining a recombinant glycoprotein antigen (NDV-3) in mouse skin and skin structure infection (SSSI)

34 Thus, needle-free, highly attenuated NDV-vectored vaccines expressing either HPAIV HA, HA(RV)

35 Current live attenuated NDV vaccines are not fully satisfactory.

36 potential to generate better live attenuated NDV vaccines.

37 farms despite the existence of high-average NDV-specific antibody titers (>4.75 log2).

38 exchanged individually between an avirulent NDV strain, LaSota, and an intermediate virulent NDV str

39 alysis of the evolutionary distances between NDV-Peru/08 and other isolates representing established

40 equired the induction of IL-17A and IL-22 by NDV-3.

41 spleen from both lines, either challenged by NDV or nonchallenged.

42 for enhanced expression of a foreign gene by NDV.

43 ) and ERdj5, in cell-cell fusion mediated by NDV glycoproteins.

44 t augmentation of innate immune responses by NDV results in selective oncolysis and offer a novel and

45 In 4-week-old chickens, NDV-DR499-31/08 behaved as a velogenic viscerotropic str

46 In 4-week-old SPF chickens, NDV-Belize-3/08 behaved as a typical velogenic viscerotr

47 Evaluations of these chimeric NDVs demonstrated that the thermostability of NDV was de

48 Also, PSA-cleavable NDV failed to replicate in chicken embryos, indicating n

49 Systemically delivered NDV fails to reach solid tumors in therapeutic concentra

50 ot belong to any of the previously described NDV genotypes.

51 miological surveillance strategies to detect NDV in wild-bird species and commercial poultry.

52 versity has been described between different NDV isolates.

53 We compared two different NDV vectors, a conventional rNDV vector and a modified r

54 At 2 dpi, NDV challenged Fayoumis had lower expression of EIF2B5 a

55 At 6 dpi, NDV challenged Fayoumis had lower expression of EIF2S3 a

56 (GFP) gene flanked by 5' and 3' UTRs of each NDV gene was individually expressed by recombinant NDVs.

57 the F and HN proteins required for efficient NDV infection and their role in avian pathogenicity.

58 and other isolates representing established NDV genotypes revealed the existence of large genomic an

59 For NDV, mesogenic (intermediate virulent) strain used in pr

60 ng the existence of an unknown reservoir for NDV.

61 reduced levels compared to what was seen for NDV-BC.

62 ew mechanism for cancer cell specificity for NDV, making it an attractive anticancer agent for chemor

63 Substitutions for NDV HN stalk residues A89, L90, and L94 block fusion by

64 ta/46 vaccine conferred full protection from NDV-Peru/08-induced clinical disease and mortality.

65 lope afforded complement resistance, we grew NDV in CHO cells stably transfected with CD46 or HeLa ce

66 t Newcastle disease virus (NDV)-vectored H7 (NDV-H7) and NDV-H5 vaccines are able to induce antibodie

67 The three vaccine viruses [NDV/HA, NDV/HA(RV), and NDV/NA] were administered separately to

68 the finding that reciprocal chimeras having NDV HN-derived heads and NiV G-derived stalks, transmemb

69 virus (NDV) expressing the MV hemagglutinin (NDV-H).

70 This is the first description of a class II NDV strain with a genome of 15,198 nt and a 6-nt insert

71 us is classified in genotype VII of class II NDV, which is genetically distinct from the commercial v

72 Lower expression of EIF2B5 was found in NDV challenged than nonchallenged Fayoumis and Leghorns

73 Higher expression of OASL in NDV challenged versus nonchallenged spleen was observed

74 antiviral pathways are highly upregulated in NDV-infected PVK cells, including genes for beta IFN, RI

75 ation studies have shown that an inactivated NDV-LaSota/46 vaccine conferred full protection from NDV

76 sponses to equivalent amounts of inactivated NDV vaccine virus.

77 whether a recombinant attenuated Indonesian NDV strain could provide better protection against preva

78 Interestingly, NDV grown in mammalian cell lines was resistant to compl

79 The incorporation of chicken RCA into NDV produced in embryonated eggs similarly provided spec

80 a virulent Newcastle disease virus isolate (NDV-Peru/08) obtained from poultry during an outbreak of

81 nidase proteins in comparison with all known NDV genotypes, suggesting the existence of an unknown re

82 ed a recombinant NDV-expressing ICOS ligand (NDV-ICOSL).

83 eal genetic diversity within and among local NDV populations in Africa.

84 d a modified NDV vector based on a mesogenic NDV strain, in which the ectodomains of envelope glycopr

85 ndidate oncolytic NDV based on the mesogenic NDV-73T strain that is no longer classified as a select

86 these concerns, we have developed a modified NDV vector based on a mesogenic NDV strain, in which the

87 The modified NDV vector was highly attenuated in chickens and was abl

88 representing an essential step toward moving NDV forward as an oncolytic agent.

89 Phylogenetic analysis of multiple NDV genotype V representatives revealed that genotype V

90 In contrast to MV, NDV-H induced high levels of type I interferon in plasma

91 between the moderately virulent, neurotropic NDV strain Beaudette C (BC) and the avirulent APMV-2 str

92 Fresh normal human serum (NHS) neutralized NDV by multiple pathways of complement activation, indep

93 d illustrates the continued evolution of new NDV strains in West Africa.

94 receptor binding and cleavage activities of NDV HN's site I while activating receptor binding by sit

95 umour models, intratumoral administration of NDV-ICOSL results in enhanced infiltration with activate

96 not affect the biological characteristics of NDV.

97 rated the feasibility of aerosol delivery of NDV-vectored vaccines.

98 cell membranes and is a major determinant of NDV pathogenicity.

99 plication, while the globular head domain of NDV HN could be replaced with that of APMV-2 with only a

100 evidence that the homologous stalk domain of NDV HN is essential for virus replication, while the glo

101 the transmembrane and cytoplasmic domains of NDV F and HN proteins, respectively, stimulated durable

102 the transmembrane and cytoplasmic domains of NDV F and HN proteins, respectively, were quantitatively

103 ; and APMV-2, containing both ectodomains of NDV.

104 lizing the exceptional oncolytic efficacy of NDV.

105 of the test and to revisit the evolution of NDV in cormorants.

106 riteria for inclusion as a novel genotype of NDV (genotype XVI).

107 these two mutations in the glycoproteins of NDV in the establishment of persistent infection.

108 meric proteins in which the globular head of NDV HN is connected to the stalk region of either human

109 ences are a marker of the natural history of NDV.

110 ribution of each protein to the induction of NDV-specific neutralizing antibodies and protective immu

111 t from all other currently known isolates of NDV, and together, they fulfill the newly established cr

112 ffect of complement on the neutralization of NDV purified from embryonated chicken eggs, a common sou

113 ant role in replication and pathogenicity of NDV in vivo.

114 fusion, tropism, and virulence phenotypes of NDV and APMV-2 and that the regions of HN that are criti

115 howed that the two contrasting phenotypes of NDV and APMV-2 could largely be transferred between the

116 We engineered the F protein of NDV and generated a recombinant NDV (rNDV) whose F prote

117 her, the data suggest that the HN protein of NDV is a crucial determinant of thermostability, and the

118 nin-neuraminidase (HN) attachment protein of NDV recognizes sialic acid receptors, whereas the NiV G

119 d colocalization of the HN and M proteins of NDV, indicating that these residues of the HN cytoplasmi

120 and M genes without altering replication of NDV, suggesting that UTRs could be used for enhanced exp

121 Indeed, stalk residues of NDV HN and MV H that likely mediate the F interaction ha

122 We show that the oncolytic selectivity of NDV for tumor cells is dependent upon tumor cell resista

123 esents the first complete genome sequence of NDV in the Dominican Republic.

124 first report of complete genome sequences of NDV strains isolated from chickens in Indonesia.

125 HN and F proteins from another strain of NDV, strain B1, could be incorporated into these VLPs.

126 Many naturally occurring strains of NDV have an intact IFN-antagonistic function and can sti

127 uding neurovirulent and avirulent strains of NDV.

128 sters are related to genotype VII strains of NDV.

129 first comprehensive and systematic study of NDV virulence and pathogenesis.

130 This substitution of NDV F into APMV-2 was sufficient to confer the neurotrop

131 G-F fusion may be more complex than that of NDV HN and F.

132 DVs demonstrated that the thermostability of NDV was dependent on the origin of HN protein.

133 Each virus induced high titers of NDV-specific hemagglutination inhibition and serum neutr

134 of NiV F by NiV G but not the triggering of NDV F by the chimeras.

135 ene probably contributes to the virulence of NDV.

136 fects of N-glycosylation of the F protein on NDV pathobiology and suggest that the N-glycans in HR1 a

137 we have generated a lead candidate oncolytic NDV based on the mesogenic NDV-73T strain that is no lon

138 haracterization of a highly potent oncolytic NDV variant that is unlikely to cause Newcastle disease

139 ase virus (NDV) isolates from this outbreak (NDV-Belize-3/08, NDV-Belize-4/08, and NDV-Belize-12/08)

140 e (OVCAR3) with a recombinant low-pathogenic NDV, persistent infection was established in a subset of

141 Compared to placebo, NDV-3A vaccination inhibited C. albicans dissemination t

142 Thus, ND VLPs are a potential NDV vaccine candidate.

143 An additional group of animals received NDV/HA by aerosol administration.

144 cell killing abilities of (i) a recombinant NDV (rNDV) strain, Beaudette C, containing an IFN-antago

145 F protein of NDV and generated a recombinant NDV (rNDV) whose F protein is cleavable exclusively by p

146 We generated a recombinant NDV, designated rLaSota/gp160, expressing the gp160 enve

147 t in the tumour, we engineered a recombinant NDV-expressing ICOS ligand (NDV-ICOSL).

148 nto the NDV genome by generating recombinant NDV-HIVGag viruses in which HIV gag was located at diffe

149 developed a genetically modified recombinant NDV (rNDV) that has much reduced pathogenicity in chicke

150 id not increase the virulence of recombinant NDV (rNDV) strain LaSota.

151 The recombinant NDV selectively replicates in and kills tumor cells and

152 genetically engineered into the recombinant NDV that reduce chicken pathogenicity to a level that is

153 This recombinant NDV has a modification at the fusion protein (F) cleavag

154 ective tumor replication of this recombinant NDV, both in vitro and in vivo, along with efficient tum

155 ne was individually expressed by recombinant NDVs.

156 and pathogenicity, we generated recombinant NDVs with a deletion or point mutation in the N-terminal

157 cy of intratumoral injections of recombinant NDVs engineered to express multiple immunotherapeutic pr

158 atumoral administration of these recombinant NDVs, particularly when combined with systemic CTLA4 che

159 erved in PVK cells infected with recombinant NDVs expressing the NiV IFN antagonist proteins V and W.

160 The eight recovered NDV HN mutants were assessed for effects on biological a

161 together, two constructs could be recovered: NDV, containing both the F and HN ectodomains of APMV-2;

162 PSA-retargeted NDV efficiently lysed prostasphere tumor mimics, suggest

163 cancer patients with immunosuppression, safe NDV-oncolytic vectors are needed.

164 fibrosarcoma, we show that the IFN-sensitive NDV variants are as effective as IFN-resistant rBC virus

165 However, unlike similar NDV HN and MV H mutants, the NiV G glycosylation stalk m

166 d lower expression of EIF2S3 and EIF2B4 than NDV challenged Leghorns.

167 d lower expression of EIF2B5 and EIF2S3 than NDV challenged Leghorns.

168 ses and neutralizing antibody responses than NDV-only immunizations.

169 Here we demonstrate that NDV possesses oncolytic activity in tumor cells capable

170 These findings demonstrate that NDV-3 protective efficacy against MRSA in SSSI involves

171 Several studies have demonstrated that NDV is selectively cytotoxic to tumor cells but not norm

172 tudies conducted with chickens revealed that NDV-Peru/08 infection results in clinical signs characte

173 Our results suggest that NDV can be used not only as a cost-effective method for

174 rall, these preclinical studies suggest that NDV-3A may serve as an immunotherapeutic strategy for pr

175 The NDV-BC F protein contains six potential acceptor sites f

176 The NDV-DR499-31/08 isolate had an intracerebral pathogenici

177 In addition, the NDV F CT has two conserved tyrosine residues (Y524 and Y

178 V-2 strain Yucaipa (rAPMV-2), containing the NDV F glycoprotein in place of its own.

179 and rAPMV3-HN, were generated expressing the NDV fusion (F) and hemagglutinin-neuraminidase (HN) prot

180 rom the RSV F protein and the other from the NDV F-protein ectodomain (F/HR2F).

181 onclude that these wild-type residues in the NDV F CT have an effect on regulating F protein biologic

182 termined the optimal insertion site into the NDV genome by generating recombinant NDV-HIVGag viruses

183 d cell surface and was incorporated into the NDV virion.

184 Sequence analysis and superposition of the NDV and hPIV-3 HN dimer structures revealed that, simila

185 transmembrane and cytoplasmic domains of the NDV F and HN proteins, respectively, stimulate durable,

186 he specific sequence of the TM domain of the NDV F protein is important for the conformation of the p

187 cytoplasmic and transmembrane domains of the NDV HN protein and the ectodomain of the human RSV G pro

188 se results support further evaluation of the NDV-3 vaccine to address disease due to S. aureus in hum

189 These results indicate that the NDV F and HN proteins are independent neutralization and

190 ent transcriptional positions throughout the NDV viral genome.

191 Thus, the NDV F protein can be triggered by binding to the NiV rec

192 ith an RSV F-protein ectodomain fused to the NDV F-protein heptad repeat 2 (HR2), transmembrane, and

193 ein, the Nipah virus G protein, fused to the NDV HN protein cytoplasmic and transmembrane domains was

194 However, the genetic basis underlying the NDV thermostability is poorly understood.

195 s did not form detectable complexes with the NDV hemagglutinin-neuraminidase (HN) protein.

196 NDV could be engineered into a thermolabile NDV vaccine strain for developing novel thermostable NDV

197 ability, and the HN gene from a thermostable NDV could be engineered into a thermolabile NDV vaccine

198 ine strain for developing novel thermostable NDV vaccine.

199 en sera devoid of neutralizing antibodies to NDV were able to effectively neutralize these virions.

200 ults showed that all three strains belong to NDV genotype V and are virulent, as assessed by the intr

201 proteins indicates that receptor binding to NDV HN site II not only can activate its own fusion (F)

202 influence the susceptibility of chickens to NDV infection.

203 In contrast to NDV infection, HeV and NiV infection of PVK cells failed

204 iptional responses of innate immune genes to NDV infection in inbred sublines of the Fayoumi and Legh

205 tribution of the large polymerase protein to NDV virulence is second only to that of the fusion glyco

206 ntribute to their differential resistance to NDV and also to understanding the interaction between pr

207 uld contribute to differential resistance to NDV in inbred Fayoumi and Leghorn lines.

208 doxical increase in apoptosis in response to NDV.

209 subline-dependent innate immune responses to NDV infection in chickens, and provide a strong framewor

210 e breeds of chickens are less susceptible to NDV infection, however, the mechanisms contributing to t

211 In a Phase 1b/2a clinical trial, NDV-3A protected women from recurrent vulvovaginal candi

212 iently expressed, bind ephrinB2, and trigger NDV F to promote fusion in Vero cells.

213 iV F by the G protein and that of triggering NDV F by the chimeras can be distinguished by differenti

214 The complete genome sequences of two NDV strains and the sequences of the surface protein gen

215 inguish this isolate from viruses of typical NDV genotypes.

216 suggesting that another mechanism underlies NDV's tumor specificity.

217 e data illustrate that it is feasible to use NDV as a vaccine vector to elicit potent humoral and muc

218 ring 2009-2010, despite intense vaccination, NDV caused major outbreaks among commercial poultry farm

219 A) protein, and we showed that this vaccine (NDV/HA) induced a high level of HPAIV-specific mucosal a

220 ge and complete protection against velogenic NDV challenge.

221 otection against virulent ILTV and velogenic NDV challenges.

222 irst complete characterization of a virulent NDV isolate from South America.

223 nferred complete protection against virulent NDV challenge.

224 erse genetics system for the highly virulent NDV strain Banjarmasin/010/10 (Ban/010) isolated in Indo

225 strain, LaSota, and an intermediate virulent NDV strain, Beaudette C (BC), and the N and P genes were

226 947 ancestral viruses suggests that virulent NDV strains may have evolved in unknown reservoirs in th

227 and mortality after challenge with virulent NDV strain Ban/010 (genotype VII) or GB Texas (genotype

228 immunized birds 21 days later with virulent NDV via the oculonasal, intramuscular, or intravenous ro

229 irus infection with Newcastle disease virus (NDV) after a 24-hour E2 treatment.

230 P and M proteins of Newcastle disease virus (NDV) and a chimeric protein containing the cytoplasmic a

231 ion (F) proteins of Newcastle disease virus (NDV) and Nipah virus (NiV) are both triggered by binding

232 , we have evaluated Newcastle disease virus (NDV) as a vaccine vector for norovirus.

233 onses by the use of Newcastle disease virus (NDV) as a vaccine vector.

234 mesogenic strain of Newcastle disease virus (NDV) as an oncolytic agent for cancer therapy has been h

235 Newcastle disease virus (NDV) belongs to serotype 1 of the avian paramyxoviruses

236 Newcastle disease virus (NDV) can cause severe disease in chickens.

237 Virulent strains of Newcastle disease virus (NDV) cause Newcastle disease (ND), a devastating disease

238 (VLPs) built on the Newcastle disease virus (NDV) core proteins, NP and M, and containing two chimeri

239 LPs) containing the Newcastle disease virus (NDV) core proteins, NP and M, and two chimera proteins (

240 MPORTANCE Oncolytic Newcastle disease virus (NDV) could establish persistent infection in a tumor cel

241 Newcastle disease virus (NDV) expressing HIV-1 BaL gp160 was evaluated either alo

242 rated a recombinant Newcastle disease virus (NDV) expressing the MV hemagglutinin (NDV-H).

243 rane (TM) domain of Newcastle disease virus (NDV) fusion (F) protein in the structure and function of

244 lycosylation of the Newcastle disease virus (NDV) fusion (F) protein in viral replication and pathoge

245 The Newcastle disease virus (NDV) fusion protein (F) mediates fusion of viral and hos

246 type 3 (HPIV-3) and Newcastle disease virus (NDV) have been previously evaluated against Ebola virus

247 active sites on the Newcastle disease virus (NDV) hemagglutinin-neuraminidase (HN) and measles virus

248 site identified in Newcastle disease virus (NDV) HN.

249 involving virulent Newcastle disease virus (NDV) in wild double-crested cormorants (Phalacrocorax au

250 ase (HN) protein of Newcastle disease virus (NDV) is a multifunctional protein that plays a crucial r

251 Newcastle disease virus (NDV) is a negative-sense RNA virus that has been shown t

252 Newcastle disease virus (NDV) is a threat to the global poultry industry, but par

253 Newcastle disease virus (NDV) is an attractive candidate for oncolytic immunother

254 Newcastle disease virus (NDV) is an oncolytic virus being developed for the treat

255 s of three virulent Newcastle disease virus (NDV) isolates from this outbreak (NDV-Belize-3/08, NDV-B

256 LPs composed of the Newcastle disease virus (NDV) nucleocapsid and membrane proteins and chimera prot

257 isease is caused by Newcastle disease virus (NDV) or avian paramyxovirus type 1 (APMV-1), a negative-

258 A Newcastle disease virus (NDV) outbreak in chickens was reported in the Dominican

259 rated a recombinant Newcastle disease virus (NDV) possessing a two-segmented genome.

260 study, we generated Newcastle disease virus (NDV) recombinants expressing glycoproteins B (gB) and D

261 study, we generated Newcastle disease virus (NDV) recombinants, based on the LaSota vaccine strain, e

262 cytoplasmic tail in Newcastle disease virus (NDV) replication and pathogenicity, we generated recombi

263 Newcastle disease virus (NDV) replication depends on the translation machinery of

264 ells expressing the Newcastle disease virus (NDV) strain AV proteins NP, M, HN (hemagglutinin-neurami

265 uence of an African Newcastle disease virus (NDV) strain isolated from a chicken in Togo in 2009 was

266 is known about the Newcastle disease virus (NDV) strains circulating in African countries.

267 Naturally occurring Newcastle disease virus (NDV) strains vary greatly in virulence.

268 ght highly virulent Newcastle disease virus (NDV) strains were isolated from vaccinated commercial ch

269 Thermostable Newcastle disease virus (NDV) vaccines have been used widely to protect village c

270 rated a recombinant Newcastle disease virus (NDV) vectoring the fusion (F) protein and glycoprotein (

271 Newcastle disease virus (NDV) was isolated from an outbreak in layer chickens in

272 nd pathogenicity of Newcastle disease virus (NDV), a green fluorescent protein (GFP) gene flanked by

273 dney (PVK) cells to Newcastle disease virus (NDV), an avian paramyxovirus known to elicit a strong in

274 eviously engineered Newcastle disease virus (NDV), an avian paramyxovirus, as a vector to express the

275 Newcastle disease virus (NDV), an avian paramyxovirus, is a promising OV and is i

276 Newcastle disease virus (NDV), an avian paramyxovirus, is inherently tumor select

277 Newcastle disease virus (NDV), an avian paramyxovirus, is tumor selective and int

278 SV), Sindbis virus, Newcastle disease virus (NDV), and Sendai virus (SeV), was significantly inhibite

279 movirus (aMPV), and Newcastle disease virus (NDV), human pathogens such as human respiratory syncytia

280 umoral therapy with Newcastle disease virus (NDV), in addition to the activation of innate immunity,

281 When infected with Newcastle Disease Virus (NDV), NOD2 expression in DCs was induced about four-fold

282 For Newcastle disease virus (NDV), one bifunctional site (site I) on HN's globular he

283 virulent strains of Newcastle disease virus (NDV), representing avian paramyxovirus serotype 1 (APMV-

284 e I IFN response to Newcastle disease virus (NDV), Sendai virus (SeV), and Semliki Forest virus (SFV)

285 and pathogenesis of Newcastle disease virus (NDV), we generated recombinant viruses with deletions in

286 lls infected with a Newcastle disease virus (NDV)-expressing VP35 redistributed DRBP76 from the nucle

287 Newcastle disease virus (NDV)-induced membrane fusion requires an interaction bet

288 Newcastle disease virus (NDV)-induced membrane fusion requires formation of a com

289 study, we show that Newcastle disease virus (NDV)-vectored H7 (NDV-H7) and NDV-H5 vaccines are able t

290 The three vaccine viruses [NDV/HA, NDV/HA(RV), and NDV/NA] were administered separa

291 ngineered six different recombinant viruses: NDVs expressing checkpoint inhibitors (rNDV-anti-PD1 and

292 behaved as a typical velogenic viscerotropic NDV strain, causing severe necrohemorrhagic lesions in t

293 ns characteristic of velogenic viscerotropic NDV strains.

294 In cotton rats immunized with NDV-H, neutralizing antibodies were also generated in th

295 To avoid potential toxicity issues with NDV, especially in cancer patients with immunosuppressio

296 reveal that active immunization in mice with NDV-3A induces high titers of anti-rAls3p-N antibodies t

297 ivo, coapplication of UV-inactivated MV with NDV led to increased MV-specific antibody production in

298 exhibited resistance to superinfection with NDV and established an antiviral state, as demonstrated

299 encouraging phase I/II clinical trials with NDV, further refinements for tumor-specific targeting ar

300 Chickens were immunized with NDVs expressing a single antigen (HA, NA, and M2), two a

301 n Mexico, clustering into a new clade within NDV subgenotype Vb.